AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03180879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference - RB Nurofen ibuprofen acid tablets
Description: RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
Study NCT02196376 — intervention group
Intervention type: OTHER
Intervention: History
Description: the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
Study NCT03180879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator - Dolormin ibuprofen lysine tablets
Description: Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
Study NCT04498247 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V591
Description: 1 or 2 ascending doses of V591 will be administered via intramuscular (IM) injection.
Study NCT04498247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (0.9% sodium chloride) administered via IM injection.
Study NCT02196376 — intervention group
Intervention type: OTHER
Intervention: Physical
Description: the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.~Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis
Study NCT02196376 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers~no more than 15 ml (1 TBSP) will be drawn.
Study NCT02196376 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.~The following questionnaires will be conducted:~RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31
Study NCT03469349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actovegin
Description: Actovegin intravenous infusion and tablets.
Study NCT03469349 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Actovegin placebo-matching intravenous infusion and tablets.
Study NCT04049903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP0310
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
Study NCT03748836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALPN-101
Description: Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
Study NCT03748836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Study NCT04867993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amikacin
Description: 15 mg/kg/36h
Study NCT04867993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin
Description: 15 mg/kg/36h
Study NCT02175134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Ascites ELISPOT
Study NCT01785225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A product type of the modified commercial drape Tegaderm (R)
Description: We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
Study NCT02523924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL PET/CT
Study NCT01321138 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
Study NCT01321138 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCA morphine
Description: Postoperative analgesia with self-administration iv morphine
Study NCT02684409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PROT-CL-NP101-015.01
Study NCT04178707 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OnZurf Probe, Senzime AB, Uppsala, Sweden
Description: Probe is inserted into the fistula and measurements are made of the inner environment.
Study NCT01735344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril Tablets 40 mg
Description: 40 mg tablet once a day
Study NCT01735344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: 40 mg tablet once a day
Study NCT03429751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 ml/Kg/h crystalloid
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 30 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Study NCT03429751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 ml/Kg/h crystalloid
Description: Lung ultrasound 8 region assessment using curvilinear 2 to 5 megahertz prob after receiving 10 ml/Kg/h crystalloid in addition to losses for maximum 3 hours.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive Ibrutinib (dose 240 mg/m\^2 /329 mg/m\^2 per day) during part 1 and part 2.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a cumulative dose of rituximab 750 mg/m\^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Participants will receive a cumulative dose of Ifosfamide 9 g/m\^2 and 10 g/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive a cumulative dose of carboplatin 635 mg/m\^2 and 800 mg/m\^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Participants will receive a cumulative dose of etoposide 300 mg/m\^2 in part 1 and part 2 as a part of RICE regimen per cycle.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Participants will receive a cumulative dose of vincristine 1.6 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 20 mg
Study NCT01133574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV354 capsules
Description: 60 mg
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Participants will receive a cumulative dose of idarubicin 20 mg/m\^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
Study NCT02703272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive a cumulative dose of dexamethasone 100 mg/m\^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
Study NCT03096678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
Study NCT04116827 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen Oral Tablet
Description: Patients who are scheduled for application of tamoxifen and goserelin
Study NCT04236518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diets with either predominantly animal protein sources.
Description: 20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from animal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
Study NCT04236518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diets with predominantly plant protein sources
Description: 20 men or postmenopausal women will follow for 4 weeks a controlled diet with a protein fraction constituted mainly from vegetal sources. At the end of the intervention period, a post-prandial exploration will be conducted with the administration of a high-fat, high-sugar meal and subsequent blood and urine sampling.
Study NCT03185715 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Oral and written counselling
Description: Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
Study NCT01921192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid, vit B6 and B12
Study NCT01921192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01283334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
Study NCT01283334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
Study NCT01283334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
Study NCT03136458 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Description: Repeated remote ischemic preconditioning by arterial cuff insufflation.
Study NCT03136458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous normal saline
Description: endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
Study NCT03136458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endovenous normal saline
Description: endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
Study NCT04091100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroacupuncture
Description: An electrical current of 2 mA and 60 Hz was administered using the Enraf Nonius Sonoplus 492 (OPTOMED) device for 20 minutes. All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
Study NCT04091100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release
Description: longitudinal stretching, friction massage and pinching technique, All the treatments were performed for 2 sessions per week for 3 weeks. Both groups were given a home program involving neck stretching and posture exercises. The exercises were to be performed at least two times a day in two sets of fifteen repetitions.
Study NCT04888442 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pCAR-19B cells
Description: Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study NCT01898221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a \~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
Study NCT01898221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
Study NCT00032188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously
Study NCT00032188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study NCT00032188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01056198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Santyl
Description: 2 mm Santyl applied once daily.
Study NCT01056198 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Daily gauze and optional sharp debridement
Study NCT00776113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol fasting
Study NCT00776113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol 12.5 mg tablets
Description: bioequivalence Carvedilol fasting
Study NCT00905281 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Group
Description: On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.~Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary.
Study NCT00905281 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: No specific intervention
Study NCT01232881 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor Sample
Description: Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
Study NCT01232881 — intervention group
Intervention type: PROCEDURE
Intervention: Serum Sample
Description: Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
Study NCT02977611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Iron sucrose will be infused at dose of 500 mg over a one hour period
Study NCT04217837 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulator
Description: Transcranial magnetic stimulation (TMS) uses a targeted pulsed magnetic field, similar to what is used in an MRI (magnetic resonance imaging) machine. While the patient is awake and alert, NeuroStar TMS Therapy stimulates areas of the brain that are underactive in depression.
Study NCT04190498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nocturnal oximetry
Description: Diagnosis of OSA will be based on the 3% Oxygen Desaturation Index (IDO) obtained by home nocturnal oximetry. The oximetry recordings will be centralized in sleep laboratory of the University Hospital of Grenoble Alpes. Oximetry data will be analyzed by a technician from the sleep laboratory of the University Hospital of Grenoble Alpes
Study NCT00824382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 2 Âµg
Description: 2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
Study NCT00824382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 5 Âµg
Description: 2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
Study NCT00824382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL 10 Âµg
Description: 2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
Study NCT00824382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 puffs delivered by the RespimatÂ® inhaler
Study NCT04376125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital inhibition in tension headache
Description: Deep maneuver of myofascial induction in the suboccipital muscles
Study NCT04376125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital inhibition in tension headache
Description: Deep maneuver of myofascial induction in the suboccipital muscles
Study NCT04649736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory and psychological rehabilitation
Description: Respiratory rehabilitation consists of 12 sessions of respiratory and physical exercises that patients perform at home with the help of a physiotherapist. Sessions have 1 hour of duration and are performing twice a week. Exercises include (1) Training of the respiratory muscles through pursed-lip breaths. (2) Effective cough exercises. (3) Diaphragmatic contractions in a supine position with a lightweight placed on the anterior abdominal wall. (4) Stretching exercise of extremities and the back.~The psychological support consists of 1 session to make the psychological history of the participant, and 6 sessions of emotion-centered problem-solving therapy, with cognitive-behavioral components and psychological management of emergencies and crises. These sessions have a 1-hour duration and are telephone-provided once a week by psychologists following the guidelines of the Inter-Agency Standing Committee on Mental Health and Psychosocial Support in Humanitarian and Disaster Emergencies.
Study NCT03277053 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
Study NCT03277053 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control.
Description: Patient receive an ipad with no application.
Study NCT01532336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVC-422 Solution, 0.3%
Description: NVC-422 Ophthalmic Solution dropped onto the eye
Study NCT01532336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NVC-422 Vehicle Solution
Description: NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
Study NCT02455258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance/Movement Therapy (DMT)
Description: Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
Study NCT02455258 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobics Exercise (AE)
Description: The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
Study NCT00129727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given intravenously
Study NCT03009877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
Study NCT03009877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC Premium Video Intubation Platform-KARL STORZ
Description: After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
Study NCT00129727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given intravenously
Study NCT00129727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously
Study NCT00858312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high dairy diet
Description: 12 week energy restriction with 3-4 servings of dairy foods/day.
Study NCT00858312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Dairy
Description: less than 1 serving of dairy foods per day.
Study NCT00940966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard ADA diet
Description: standard ADA diet
Study NCT00940966 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: energy restricted very-low carbohydrate diet
Description: energy restricted very-low carbohydrate diet